Molecular Formula | C16H13F3N4O |
Molar Mass | 334.3 |
Density | 1.43±0.1 g/cm3(Predicted) |
Boling Point | 493.4±45.0 °C(Predicted) |
Solubility | DMSO: ≥ 36 mg/mL |
pKa | 2.92±0.40(Predicted) |
Storage Condition | -20℃ |
In vitro study | In the H2122 and H358 cell lines, BQU57 inhibited RalA and RalB activation, resulting in cell growth inhibition. |
In vivo study | In mice bearing human lung H2122 tumors, BQU57 (50 mg/kg, I. p.) significantly inhibited the activation of RalA and RalB and caused dose-dependent tumor growth inhibition. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.991 ml | 14.957 ml | 29.914 ml |
5 mM | 0.598 ml | 2.991 ml | 5.983 ml |
10 mM | 0.299 ml | 1.496 ml | 2.991 ml |
5 mM | 0.06 ml | 0.299 ml | 0.598 ml |
biological activity | BQU57, a derivative of RBC8, is a selective GTPase Ral inhibitor relative to GTPases Ras and RhoA. |
target | TargetValue GTPase Ral () |
Target | Value |
in vitro study | in H2122 and H358 cell lines, BQU57 inhibits the activation of RalA and RalB, thus causing cell growth inhibition. |
in vivo study | in mice loaded with human lung H2122 tumors, BQU57 (50 mg/kg, I. p.) significantly inhibited the activation of RalA and RalB and caused dose-dependent tumor growth inhibition. |